CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
1. Cretostimogene shows 41.8% complete response rate at 24 months. 2. 90% of 12-month responders remain disease-free at 24 months. 3. No serious adverse events reported, indicating good safety profile. 4. CG Oncology plans to submit BLA for cretostimogene by Q4 2025. 5. Study represents the largest cohort of heavily pretreated NMIBC patients yet.